Thermo Fisher Scientific Inc., US8835561023

Thermo Fisher stock: CEO points to stronger 2027 growth

Published on 11/20/2026 at 00:05 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Thermo Fisher Scientific stock faces a steadier 2027 outlook as CEO Marc Casper sees improving demand across pharma, biotech and China. Formal guidance follows in February.

Thermo Fisher sees steadier recovery

  • Management expects 2027 growth to strengthen within its 3 to 6 percent organic growth framework.
  • Pharma and biotech demand is improving, while academic spending and China are showing early signs of recovery.
  • Formal 2027 guidance is due in early February.
Thermo Fisher Scientific Inc., US8835561023, Illustration mit AI erstellt.

Thermo Fisher Scientific said on Thursday, November 19, that it expects growth to strengthen in 2027 as pharmaceutical and biotech spending improves and academic demand stabilizes. The outlook was presented by Chairman and CEO Marc Casper during the UBS 2026 CEO Call Series, according to Investing.com.

Management sees recovery broadening

Casper said Thermo Fisher expects 2027 organic growth to strengthen from 2026 while remaining within the company's 3 to 6 percent framework. The company plans to provide formal 2027 guidance in early February.

Pharma and biotech, which account for about 60 percent of revenue, delivered high-single-digit growth in the third quarter, according to the transcript. Management also pointed to more stable academic and government spending and low-double-digit growth in China in recent quarters.

Thermo Fisher said the recovery is not yet at its peak in several end markets. Biotech funding is improving, while early-stage research spending remains softer and could benefit as customers rebuild pipelines. Management highlighted artificial intelligence, reshoring, proteomics and clinical development tools as additional growth drivers.

Current trading level

Thermo Fisher Scientific stock traded at 615.80 euros on Lang & Schwarz at 23:00 CET on Thursday, November 19, 2026.

The company's message combines a more predictable market backdrop with continued execution across its portfolio. Investors will look to the February update for the formal 2027 outlook and any indication that improving end markets are translating into broader demand.

Business spans science and healthcare

Thermo Fisher Scientific supplies laboratory technologies, analytical instruments, diagnostics and pharmaceutical services. Its brands include Thermo Scientific, Applied Biosystems, Invitrogen, Gibco, Fisher Scientific, Unity Lab Services, Patheon and PPD. The company serves life sciences research, laboratory operations, diagnostics and the development and manufacture of therapies from its base in the United States.

Thermo Fisher Scientific at a glance

  • Company: Thermo Fisher Scientific Inc.
  • ISIN: US8835561023
  • Ticker: TMO
  • Home exchange: New York Stock Exchange
  • Lang & Schwarz quote: 615.80 euros on November 19, 2026 at 23:00 CET
  • Sector: Life Sciences Tools and Services

The US market environment is followed through the S&P 500.

More news and analyses on Thermo Fisher Scientific stock.

Disclaimer...
en | US8835561023 | THERMO FISHER SCIENTIFIC INC. | boerse | 70538146 | bgmi